Track topics on Twitter Track topics that are important to you
European regulators have given Sirakoss CE mark approval for Osteo3, a nanosynthetic bone graft substitute with a surface che -More-
Osteo3 is a nanosynthetic bone graft substitute designed to improve patient healing and providing surgeons with a more advanced solution for repairing bone fractures. Synthetic bone grafts are The po...
Represents New Hope for Repairing Challenging Bone Fractures SIRAKOSS Ltd, a developer of unique synthetic bone graft substitutes, announced today it has been granted CE Mark ...
It is not anticipated that the recently ended record US government shutdown will have a long-term impact on US FDA...
US FDA issued only one warning letter directly related to medical device advertising or promotion in 2018. But that doesn’t...
SIRAKOSS is developing nanosynthetic graft substitutes to facilitate complete bone repair and transform patient healing. The SIRAKOSS bone graft substitutes utilise advanced and p...
We have published hundreds of SIRAKOSS Ltd news stories on BioPortfolio along with dozens of SIRAKOSS Ltd Clinical Trials and PubMed Articles about SIRAKOSS Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SIRAKOSS Ltd Companies in our database. You can also find out about relevant SIRAKOSS Ltd Drugs and Medications on this site too.
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...
Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...